Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

97.28USD
6:23pm BST
Change (% chg)

$1.36 (+1.42%)
Prev Close
$95.92
Open
$95.92
Day's High
$97.49
Day's Low
$95.64
Volume
383,998
Avg. Vol
1,830,954
52-wk High
$125.84
52-wk Low
$69.47

Latest Key Developments (Source: Significant Developments)

AbbVie Q2 Adjusted Earnings Per Share $2.00
Friday, 27 Jul 2018 

July 27 (Reuters) - AbbVie Inc ::QTRLY EARNINGS PER SHARE $1.26; QTRLY ADJUSTED EARNINGS PER SHARE $2.00;.QTRLY NET REVENUE $8.28 BILLION, UP 19.2 PERCENT; QTRLY ADJUSTED NET REVENUE $8.26 BILLION, UP 17.1 PERCENT ON OPERATIONAL BASIS.Q2 EARNINGS PER SHARE VIEW $1.97, REVENUE VIEW $8.21 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY GLOBAL HUMIRA SALES OF $5.19 BILLION, UP 10 PERCENT ON REPORTED BASIS.QTRLY GLOBAL IMBRUVICA NET REVENUE $850 MILLION, UP 35.6 PERCENT.SEES 2018 EARNINGS PER SHARE $6.47 TO $6.57; SEES 2018 ADJUSTED EARNINGS PER SHARE $7.76 TO $7.86.FY2018 EARNINGS PER SHARE VIEW $7.81 -- THOMSON REUTERS I/B/E/S.RAISING FY 2018 EPS GUIDANCE.TO EXPERIENCE ONE-TIME NET TAX BENEFIT IN 2018 RELATED TO TIMING OF PHASE IN OF PROVISIONS OF NEW LEGISLATION ON SOME UNITS.  Full Article

Neurocrine Biosciences Says $40 Mln Event-Based Payment To Be Made To Co By Abbvie
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Neurocrine Bioscience::NEUROCRINE BIOSCIENCES - WITH FDA APPROVAL OF ORILISSA, $40 MILLION EVENT-BASED PAYMENT WILL BE MADE TO CO BY ABBVIE UNDER COLLABORATION AGREEMENT.NEUROCRINE BIOSCIENCES - $40 MILLION EVENT-BASED PAYMENT BY ABBVIE TO CO TO BE RECOGNIZED AS REVENUE BY CO IN Q3.  Full Article

AbbVie Receives U.S. FDA Approval Of Orilissa
Tuesday, 24 Jul 2018 

July 24 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES U.S. FDA APPROVAL OF ORILISSA™ (ELAGOLIX) FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS.ABBVIE INC - ORILISSA IS EXPECTED TO BE AVAILABLE IN U.S. RETAIL PHARMACIES IN EARLY AUGUST 2018.  Full Article

Abbvie Says It Submitted Supplemental NDA To U.S. FDA For Venetoclax
Thursday, 12 Jul 2018 

July 12 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION TO US FDA FOR VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY.  Full Article

Abbvie Inc - Director Glenn Tilton Reports Open Market Purchase Of 5,400 Shares Of Common Stock
Friday, 29 Jun 2018 

June 29 (Reuters) - AbbVie Inc ::ABBVIE INC SAYS DIRECTOR GLENN TILTON REPORTS OPEN MARKET PURCHASE OF 5,400 SHARES OF COMMON STOCK AT AVERAGE PRICE OF $91.90PER SHARE ON JUNE 27 - SEC FILING.  Full Article

Imbruvica (Ibrutinib) Supplemental New Drug Application Accepted For Review By U.S. FDA
Monday, 25 Jun 2018 

June 25 (Reuters) - AbbVie Inc ::IMBRUVICA® (IBRUTINIB) SUPPLEMENTAL NEW DRUG APPLICATION ACCEPTED FOR REVIEW BY U.S. FDA WITH POTENTIAL TO BROADEN TREATMENT USE AS A COMBINATION TREATMENT OPTION WITH RITUXIMAB IN WALDENSTRÖM'S MACROGLOBULINEMIA (WM), A RARE FORM OF BLOOD CANCER.ABBVIE INC - SNDA BASED ON DATA FROM PHASE 3 INNOVATE STUDY, SUGGESTING IMBRUVICA PLUS RITUXIMAB MAY IMPROVE OUTCOMES ACROSS ALL LINES OF WM.  Full Article

AbbVie And Calibr Announce Collaboration For Next Gen T-Cell Therapies
Monday, 25 Jun 2018 

June 25 (Reuters) - AbbVie Inc ::ABBVIE AND CALIBR ANNOUNCE COLLABORATION FOR NEXT GENERATION T-CELL THERAPIES.ABBVIE INC - COLLABORATION WILL FOCUS ON SWITCHABLE CAR-T THERAPIES AIMED PRIMARILY AT SOLID TUMORS.ABBVIE - WILL PAY CALIBR UPFRONT LICENSE FEE AND GAIN EXCLUSIVE ACCESS TO CALIBR'S SWITCHABLE CAR-T PLATFORM FOR A TERM OF UP TO FOUR YEARS.ABBVIE INC - ALSO HAS OPTION TO DEVELOP ADDITIONAL CELL THERAPIES TOWARD ABBVIE-NOMINATED TARGETS.ABBVIE - ALSO HAS OPTION TO LICENSE EXISTING CALIBR CELL THERAPY PROGRAMS UNDER DEVELOPMENT FOR HEMATOLOGICAL & SOLID CANCERS.  Full Article

FDA Approves Abbvie & Genentech USA's VENCLEXTA For Treating Two Types Of Blood Cancers
Friday, 8 Jun 2018 

June 8 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVED ABBVIE & GENENTECH USA'S VENCLEXTA FOR TREATING PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA.  Full Article

AbbVie Inc Says On May 17, Entered Loan Credit Agreement To Borrow Up To $3 Bln
Friday, 18 May 2018 

May 18 (Reuters) - AbbVie Inc ::ABBVIE INC - ON MAY 17, ENTERED TERM LOAN CREDIT AGREEMENT TO BORROW TERM LOANS ON AN UNSECURED BASIS OF UP TO $3 BILLION - SEC FILING.  Full Article

Abbvie Submits Marketing Authorization Application To EMA For Investigational Treatment Risankizumab For Moderate To Severe Plaque Psoriasis
Tuesday, 1 May 2018 

May 1 (Reuters) - AbbVie Inc ::ABBVIE SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR INVESTIGATIONAL TREATMENT RISANKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS.ABBVIE INC - APPLICATION SUPPORTED BY FOUR PIVOTAL PHASE 3 TRIALS EVALUATING MORE THAN 2,000 PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.  Full Article

US STOCKS-Tech stocks weigh on Wall Street

* Indexes down: Dow 0.3 pct, S&P 0.66 pct, Nasdaq 1.46 pct (Updates to close)